Skip to main content

Security report for ibsauk.co.uk

IBSA Pharma UK · Healthcare · United Kingdom

Medium risk. 3 critical or high findings in Email security, SSL/TLS and 1 other check.

Security score

61/100

Risk levelMedium

0–100, higher is better. How it is calculated

IBSA Pharma UK is a subsidiary of the Swiss multinational pharmaceutical company IBSA Institut Biochimique SA, with a strong international presence and a history dating back to 1945. The company focuses on pharmaceutical products across multiple therapeutic areas and emphasizes sustainability and corporate responsibility. The website reflects a professional corporate identity targeting healthcare professionals and partners. Technically, the site uses modern web technologies including Bootstrap, jQuery, Google Analytics, and OneTrust for cookie consent, indicating a mature digital infrastructure. Security posture is good with HTTPS enforced and secure forms, though additional security headers could enhance protection. Privacy compliance is strong with clear policies and consent mechanisms. The WHOIS data for the domain is unavailable due to a naming rules error, suggesting the domain may be a subdomain or alias, which slightly reduces trust but does not undermine the legitimacy of the business. Overall, the website is well-structured, secure, and compliant, supporting the company's credibility in the pharmaceutical sector.

Scanned

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • Critical

      Unable to retrieve SSL certificate

      Could not establish secure connection to retrieve certificate information

      What to do: Check if the server is accessible and SSL/TLS is properly configured

  3. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

Need hands-on remediation? Email guard@offseq.com

Keep watching ibsauk.co.uk

This scan found 17 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
0
Security headers
45
Email security
60
DNS health
75
Network security
100
GDPR outside view
88
Average
61

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention ibsauk.co.uk, from OffSeq Breach.

No leaked records found

Breach holds no records for ibsauk.co.uk right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.

Monitor on Breach (opens in a new tab)

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

IBSA Pharma UK operates within the healthcare sector as an essential entity, leveraging a multinational business model with subsidiaries across Europe, Asia, and the Americas. The company benefits from a strong brand and parent company support, with a diversified portfolio in therapeutic areas such as reproductive medicine, osteoarticular, and consumer health. The website's linkage to multiple regional subsidiaries and partner sites indicates a broad partnership ecosystem. The business model focuses on pharmaceutical manufacturing and distribution, targeting healthcare professionals and markets in over 90 countries. Growth indicators include recent acquisitions and sustainability initiatives. The company maintains a professional online presence with comprehensive corporate documentation and contact channels, supporting business credibility and market positioning.

Security posture

The website demonstrates a solid security posture with HTTPS enforced and secure form handling including CSRF tokens. The presence of a cookie consent mechanism aligns with GDPR compliance. However, the absence of several recommended security headers such as Content-Security-Policy and X-Frame-Options represents an area for improvement. No vulnerabilities or exposed sensitive data were detected in the HTML content. Incident response and vulnerability disclosure information are not present on the site, which could be enhanced to improve transparency and readiness. Overall, the security maturity is good for a corporate pharmaceutical website, with room for strengthening header policies and incident response visibility.

Recommendations

  1. Implement additional HTTP security headers including Content-Security-Policy, X-Content-Type-Options, X-Frame-Options, and Referrer-Policy to enhance protection against common web attacks.
  2. Publish explicit incident response and vulnerability disclosure policies to improve transparency and readiness for security events.
  3. Enhance accessibility features to meet higher compliance standards and improve user experience for all visitors.
  4. Regularly audit and update third-party libraries and scripts to mitigate potential vulnerabilities.
  5. Consider verifying and publishing WHOIS domain registration details or clarifying domain structure to improve trust and legitimacy perception.

Contact details published on the site

Addresses
Legal name
IBSA Pharma UK
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
IBSA Pharma UK
Description
IBSA Pharma® Ltd became an affiliate of IBSA Institut Biochimique SA (IBSA), following the acquisition of its UK distributor Pharmasure® in May 2022. IBSA is a Swiss multinational pharmaceutical company founded in 1945 in Lugano, with products present in over 90 countries and 20 subsidiaries worldwide.
Key services
Pharmaceutical products, Therapeutic areas coverage, Corporate and sustainability reporting
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.7.1, Bootstrap, Google Analytics, Google Tag Manager, OneTrust Cookie Consent, Swiper.js, LazySizes, Select2
Frameworks
Bootstrap
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML
  • Secure forms with CSRF tokens (hidden field present)

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Marketing tools
OneTrust Cookie Consent
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenge
  2. Professional pharmaceutical corporate website with clear branding
  3. Comprehensive privacy and cookie policies with consent mechanism
  4. WHOIS data unavailable due to domain naming rules error
  5. Multiple external links to related IBSA group subsidiaries and partner sites
  6. No suspicious or malicious content detected
  7. Good use of modern web technologies and analytics
  8. Contact information clearly provided with UK address and phone
  9. No explicit security or incident response policies found on site
Technical notes

Notes

The website is built on a modern technology stack including Bootstrap for responsive design, jQuery for DOM manipulation, and Swiper.js for interactive sliders. Google Analytics and Google Tag Manager are used for analytics and tracking, integrated with OneTrust for cookie consent management. The site appears to be hosted on a platform consistent with Adobe Experience Manager, indicated by DAM/JCR resource paths. Performance is moderate with lazy loading and responsive images implemented. Mobile optimization is good, and SEO practices are evident through meta tags and structured navigation. Accessibility is basic but could be improved. No critical technical debt or legacy technology was detected, indicating a well-maintained infrastructure suitable for a large multinational pharmaceutical company.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with ibsauk.co.uk. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review ibsauk.co.uk.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.